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Biology has always been a heavily technology limited field. Burgeoning fields such as systems 
biology require the development and implementation of new technologies, enabling high-
throughput and high-fidelity measurements of large systems. Microfluidics promises to fulfil many 
of the requirements put forth. Here I will discuss the various approaches employed to date for 
performing high-throughput screening experiments on-chip, encompassing biochemical, 10 
biophysical, and cell-based assays.
Introduction 
Advances in our understanding of biological systems have 
invariably been linked to antecedent innovation in technology. 
This symbiosis is apparent since the early days of biology 15 
when Robert Hooke coined the term “cell” and the discovery 
of bacteria by Antonie van Leeuwenhoek. A preceding 
advance in engineering enabled both of these discoveries: the 
invention of the microscope by dutch lens makers or possibly 
Galileo Galilei. More recent examples of how engineering and 20 
physics impact biology include the use of optics1, mass 
spectrometry2, 3, microarrays4, 5, atomic force microscopy6, 7, 
optical tweezers8-10, and micro- and nano-electromechanical 
sytems (MEMS and NEMS)11, 12. Of course biology itself gave 
rise to novel methodologies and approaches such as the 25 
polymerase chain reaction13, molecular cloning, enzyme 
linked immunosorbent assays (ELISAs)14, chromatin immuno 
precipitation (ChIP)15-18, yeast two hybrid screening19-21, and 
the green fluorescent protein22.  
 In this review I will focus on microfluidics, one such recent 30 
engineering advance being applied to biology with ever 
increasing success. A microfluidic device, in its simplest 
form, consists of a channel with cross-sectional dimensions on 
the order of tens to hundreds of microns. Such devices, used 
for capillary electrophoresis, were first described in the early 35 
1990’s23, 24. Since then the field has evolved ever more 
complex next-generation devices leading to the development 
of microfluidic large-scale integration (MLSI)25, 26. MLSI 
allows for the integration of thousands of micromechanical 
valves on a single device with a postage-sized footprint. 40 
Microfluidics is becoming increasingly appealing to biologist 
due to recent trends in the biological sciences necessitating 
exceedingly large and comprehensive experiments27-29. 
Several characteristics intrinsic to microfluidic systems make 
high-throughput screening of biological systems feasible and 45 
likely a standard practice in the near future: 
i. Unrivalled economy of scale. Microfluidics 
significantly lowers screening cost by drastically 
reducing reagent consumption by multiple orders of 
magnitude. 50 
ii. Through the reduction in length scales it is possible 
to perform thousands of experiments on a small 
footprint enhancing assay integration. 
 
Fig. 1 Publication History. A rough estimate of the number of journal 55 
articles published each year since 1993 as determined by using a simple 
keyword search (Microfluidic*) in Web of Science. The red bars show all 
articles recovered with microfluidic* as their topic. Blue bars show the 
fraction of articles falling into a biology related subject area. We can 
glean from this graph that: the field has grown exponentially over the last 60 
decade, and a constant 32% of microfluidic articles are biology related  
(inset). 
iii. Microfluidics provides novel processes and detection 
mechanisms, not achievable on larger length-scales. 
Because of these unique and promising characteristics 65 
microfluidic devices have been applied to essentially all major 
classical biological methods such as PCR30-33, cloning34, 
separations35-38, in vitro protein synthesis39, 40, drug 
screening41, cell based screens42-48, small molecule 
synthesis49, DNA/peptide synthesis50-53, enzyme screens54, 70 
protein interaction screening55, and crystallography56-59. Many 
of these examples describe the simple reduction of classical 
bench-top methods to microfluidic scales, which in many 
cases are accompanied by beneficial effects such as reduction 
in reaction times, increased sensitivity, and of course 75 
decreased reagent consumption. Microfluidic screens that 
allow for a drastically increased throughput as compared to 
their classic bench-top counterparts (if a classical counterpart 
even exists) are of particular interest, especially in light of the 
burgeoning field of systems biology. It is these high-80 
throughput microfluidic screens that are discussed in this 
review. The goal of this review therefore is to provide an 
overview of recently developed microfluidic screening 
platforms, covering all major approaches to screening and 
high-throughput experimentation. This review necessarily 85 
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covers a very small cross-section of the existing literature due 
to the large number of devices fabricated to date (Fig. 1), but 
nonetheless aims to achieve a comprehensive coverage of 
available approaches. Other reviews discuss the application of 
microfluidics to systems biology, particularly life cell imaging 5 
and cell culturing60, 61. Megason and Fraser specifically 
discuss imaging in systems biology in a separate review28. 
Fluid physics, as observed on microfluidic platforms, is 
comprehensively summarized by Squires and Quake62. 
 High-throughput microfluidic screens can be classified into 10 
two primary categories depending on whether the molecules 
or cells to be screened are introduced into the device 
randomly or systematically. Random introduction of material 
generally involves a heterogeneous mixture or suspension, 
which is directly introduced onto the device without pre-15 
processing. On-chip the solution is aliquoted into sufficiently 
small volumes, such that each aliquot on average contains one 
quantum of the original heterogeneous mixture or suspension. 
Each aliquot can then be individually screened for function. 
Systematic approaches involve the introduction of 20 
homogeneous solutions to precise locations on a device. These 
solutions may then be screened directly, or can be combined 
to give rise to a larger screening space. Both random and 
systematic screening methods can be further sub-classified by 
whether the reactions take place in series or in parallel. Below 25 
I will give a few examples covering all four screening 
approaches and discuss advantages and disadvantages 
involved with each, hopefully providing a comprehensive 
overview to biologists interested in finding and applying the 
most appropriate microfluidic approach to their specific 30 
experimental requirement. 
Random Screens 
Serial Devices 
Probably the most familiar serial-random screening approach 
is flow cytometry63-65. Here, a heterogeneous mixture of cells 35 
is introduced into a capillary channel, which permits only 
single cells to pass by a detector with an inter-cell distance 
dependent on the initial cell density. More sophisticated flow 
cytometers make use of laminar flow to hydro-dynamically 
focus the cells into the centre of the channel. One or several 40 
laser lines are used to excite specific fluorophores, which 
were previously attached to the cells using fluorescently 
labelled antibodies or other fluorescent dyes66, and the emitted 
photons are detected with photomultiplier tubes (PMTs). 
Fluorescent proteins such as GFP have also been used for 45 
detection67. In a special type of flow cytometer, the 
fluorescent-activated cell sorter (FACS), cells are flown past 
one or more T-junctions after the detector. At these junctions 
cells with a specific pre-determined fluorescent fingerprint 
can be sorted from the bulk. 50 
 The throughput of flow cytometry is one of the highest 
achieved to date. Commercially available flow cytometers and 
FACS sorters can measure and sort on the order of 20’000 
cells/second. No other device is more adapt at quantitative 
measurements of whole cell fluorescence in multiple 55 
wavelengths. Additionally, FACS is an exceedingly powerful 
approach for enriching rare cells, such as stem cells68, from a 
heterogeneous population for downstream processing. 
 But performance comes with a hefty price tag, causing most 
flow cytometers and FACS instruments to be found in core 60 
facilities rather than in individual research labs. Recently, 
microfluidic research groups have manufactured one-time use 
microfluidic FACS69-72. But even though the performance of 
these simple and cheap devices lags behind that of 
commercial machines, there is no fundamental reason why, 65 
with additional improvements, these microfluidic throwaway 
FACS can’t reach acceptable levels of performance making 
them effective alternatives for many basic flow cytometry and 
sorting experiments. 
 A more fundamental limitation of flow cytometry is the fact 70 
that individual cells are measured only once, and can’t be 
interrogated over a period of time (a cytometer developed by 
Voldman et al. based on dielectrophersis for cell trapping is 
one exemption to this rule69). Researchers have measured 
populations of cells over a period of time, but the time-75 
dependent information from a single cell is not accessible67. 
Finally, flow cytometry generally lacks the high-spatial 
resolution necessary for determining sub-cellular localization 
of proteins28. For experiments requiring the measurement of 
these types of parameters it is necessary to apply either 80 
random or systematic parallel cell arrays (described below). 
 
Parallel Devices 
In random-parallel devices a heterogeneous mixture is 
introduced and aliquoted into sufficiently small volumes so 85 
that each unit volume on average contains a single cell or 
molecule, thus homogenizing the mixture. We previously 
applied such a screening methodology to the directed 
evolution of an enzyme (Fig. 2)25. In directed evolution73 an 
open reading frame (ORF) coding for a protein (generally an 90 
enzyme) of interest is randomly mutagenized, commonly via 
error-prone PCR. The resulting heterogeneous mixture of PCR 
products is then cloned into a vector, which in turn is 
transformed into a host, generally E.coli. The heterogeneous 
mixture of cells is then “purified” by spread plating the cells. 95 
The resulting clonal colonies are picked and placed into 
multiwell plates, where they can be grown and the mutant 
proteins tested for function using an appropriate assay. This is 
an extremely labour intensive process, particularly because 
tens of thousands of clones should be picked and assayed in 100 
order to ascertain that improved versions of the original 
protein are found. We designed a complex microfluidic device 
that allowed us to commence the screening and selection step 
directly on the heterogeneous mixture of transformants25. This 
was achieved by introducing the cell mixture into a long 105 
serpentine microfluidic channel. Once loaded, the channel 
could be compartmentalized into 256 chambers of 375pL and 
doing so would give on average ~1 cell/chamber (if the initial 
cell density was adjusted appropriately). A specific substrate 
was introduced into each chamber by passive diffusion which, 110 
when turned-over by the enzyme expressed in each cell, 
becomes fluorescent. The entire device could be quantitated 
using a standard DNA microarray scanner. The recovery of  
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Fig. 2 MLSI Device For Single Cell Screening (a) An optical micrograph of the device with its channels filled with food dyes for visualization. The 
device contains 2056 micromechanical valves on a 2.5 cm x 2.5 cm footprint. Heterogeneous populations of E. coli cells could be introduced onto the 
device followed by compartmentalization and imaging (b). Once individual cells were trapped in one of the 256 chambers of the device, an enzyme assay 
could be performed, generating signal only in chambers containing one or more cells (c). (d) Quantitation of the observed signals normalized by the 5 
number of cells from which the signal originated gave rise to broadly distributed signal levels. (adapted with permission from reference 25)
 
 
Fig. 3 Microfluidic Cell Isolation Array Eight parallel channels 10 
containing trapping arrays were used to dynamically trap both HeLa as 
well as Jurkat cell lines. Trapping is accomplished with cup-shaped posts 
hanging from the roof of the channel. Depending on the size of the cup, 
one or multiple cells may be immobilized in each trap. (adapted with 
permission from reference  43) 15 
the clone of interest was accomplished using a microfluidic 
analogue of a multiplexer allowing each chamber to be 
individually addressed. Single E.coli cells were successfully 
recovered from the device followed by growth on an LB-agar 
plate demonstrating the feasibility of the approach. 20 
 These measurements present one of the few single cell 
high-throughput enzyme measurements to-date. But, due to 
the large intrinsic noise of the biological system we observed 
a broad distribution of signal even for a homogeneous 
population of cells, all expressing wild type enzyme74. Noise 25 
on the single cell level can arise, amongst other factors, from 
varying plasmid copy numbers, which translate into differing 
enzyme concentrations, or from cells being in different parts 
of the cell cycle (or dead). To correct for this it is necessary to 
either normalize the observed signal with the exact 30 
concentration of enzyme present (rather than assuming that 
each cell roughly contains the same number). A second 
approach would be growing clonal populations of cells on-
chip starting from the compartmentalized single cells. 
 Throughput of less than 256 (not all chambers contain 35 
exactly a single cell due to the random seeding process) for 
this proof-of-principle experiment must also be improved in 
order to make it a feasible method for screening in directed 
evolution. This could be accomplished by using pooling or 
enrichment strategies, using a modified microfluidic design. 40 
Such an optimized screening platform would provide 
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significant savings in assay time, labour, and cost, when 
compared to the currently used approach. 
 Another recently developed device by Lee et al. is capable 
of generating large arrays of cells, randomly immobilized in 
small fluidic traps (Fig. 3)43. The fluidic traps consist of 5 
small, cup-shaped PDMS posts hanging from the roof of the 
device. Each post is suspended roughly 2 microns above the 
floor of the channel. This gap is sufficient to allow fluid to 
flow beneath the post. If a solution of cells is added to the 
device the cells will be dragged next to the cup-shaped post. 10 
Once next to the post a cell is trapped in that location. A 
better than random trap occupancy was observed for single 
cells on these devices. Lee et al. were able to trap both HeLa 
and Jurkat cells on the device and ran time-dependent enzyme 
assays on the trapped cells. This trapping device is a simple, 15 
yet efficient approach to generating large random arrays of 
cells. Furthermore, by turning of the flow, or reversing it, the 
arrays can be regenerated, allowing for multiple consecutive 
trapping runs. One drawback of the approach is the fact that 
cells being screened can’t be specifically recovered from the 20 
device, as would be necessary when screening for directed 
evolution, or if downstream processing of a single cell is 
required. Also, due to the method of trapping, arraying 
smaller cells such as bacteria may prove difficult. But for 
many applications not requiring recovery or trapping of small 25 
cells, this device is a perfect solution to generating random 
screening diversity. 
 
Random Screens Summary 
Random high-throughput screening devices work on the 30 
principal of serial analysis of small sample volumes or use 
homogenization by compartmentalization in combination with 
parallel screening to simplify a complex input mixture. 
Random-serial devices such as flow cytometers are capable of 
extremely high-throughput and have been widely applied to 35 
biology. Random-parallel devices are more complex and thus 
generally have drastically reduced throughput, but they allow 
for complex fluidic assays to be performed and permit the 
continuous interrogation of each compartment. 
 It probably also has become apparent that random screening 40 
devices work well using cells as input. This is because cells 
nicely package their contents, and their length-scales are 
sufficiently matched to the length scales of the microfluidic 
devices that they become relatively easy to manipulate. Cells 
are also readily detectable using standard microscopy. There 45 
is no limiting factor that would prevent single molecules from 
being assayed using similar approaches as described above. 
Screening of single molecules does require that the genotype 
and phenotype remain linked throughout the assay. This can 
be accomplished using compartmentalization. One gedanken 50 
assay would for example include compartmentalization of 
single plasmids coding for an enzyme into microfluidic 
chambers followed by on-chip in vitro transcription / 
translation followed by an appropriate readout. If necessary, 
additional steps like PCR for amplification before or after 55 
protein synthesis could be included as well. 
 Flow cytometry is not directly applicable to those types of  
 
Fig. 4 Microfluidic Droplets and Plugs Two approaches for generating 
water / oil or water / oil / gas droplets and plugs. (a) A scheme for the 60 
rapid generation of varying ratios between 3 input streams, for the 
comprehensive screening of crystallization conditions. The photos on the 
left show the entire device as well as crystals contained in small water 
droplets. (b) Water, oil, or gas (air) plugs can also be used for high-
throughput screening of crystallization conditions. (adapted with 65 
permission from references 57, 75) 
experiments because the genotype-phenotype linkage is not 
preserved. But, when combined with water / oil (w/o) 
emulsions or microfluidic droplet generation, flow cytometry 
has the potential of becoming an exceedingly high-throughput 70 
approach to screening complex molecular libraries. 
Systematic Screens 
Serial Devices 
Water / oil (w/o) emulsions have recently been applied with 
great effect to the clonal amplification of single DNA 75 
molecules for use in second-generation sequencing76. A wide 
range of droplet sizes from tens of pL to nL can be formed by 
mixing two immiscible liquids.  Monodispersed droplets or 
plugs can be formed precisely and on the order of thousands 
per second on microfluidic devices77-81. More importantly, 80 
each droplet can be formulated from a combination of several 
input streams systematically generating diverse droplets56, 57, 
75. Once generated, droplets can be manipulated on an 
individual basis, such as merging adjacent droplets82, 83, 
dividing a single droplet82, 84, and even extracting the contents 85 
of a single droplet into a continuous fluid stream85. These 
characteristics make on-chip droplet formation and handling 
interesting for high-throughput screening. 
 Rustem F. Ismagilov’s group at the University of Chicago 
has successfully applied dynamic droplet formation to protein 90 
crystallography (Fig. 4)56, 57. One has to test a large 
combinatoric space of precipitating agents over a wide range 
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of concentrations to find a condition in which a given protein 
will crystallize. Exacerbating that difficulty is the fact that 
many proteins of interest are also exceedingly difficult to 
purify in quantities required for standard crystallization 
screens. Reducing the reaction volumes from tens of 5 
microliters down to sub-nanoliter volumes entails a huge 
benefit by either requiring less protein for the same number of 
screens or allowing for a larger search space with the same 
amount of material. 
 Ismagilov and co-workers generate programmable droplets 10 
by combining 3-4 water streams containing protein, buffer and 
various precipitating agents. Mixing ratios are adjusted by 
changing the relative pressures in these feed channels. The 
laminar water streams are then sheared off by the oil phase 
and the contents of the droplets either mix diffusively or by 15 
active mixing. Droplets are routed along a holding channel 
where they can be stored and interrogated after a given 
amount of time. Glass capillaries have been used for storage 
channels to avoid solution evaporation57, which was observed 
when channels made from PDMS were used for long term 20 
storage56. These initial microbatch reactions spanned a low 
dimensional phase space of conditions consisting of at most 
two crystallization agents. Increasing the dimensionality of 
this system to tens of crystallization reagents should 
nonetheless be possible and probably necessary to make the 25 
approach more broadly applicable. 
 Vapour-diffusion reactions were also created by placing 
two droplets with differing osmotic pressures in close 
proximity57. Water moves by diffusion from one droplet to its 
neighbour causing a time-dependent change in volume and 30 
thus concentration of each droplet. With this method it is 
possible to dramatically increase the number of conditions 
tested by continuously moving through a concentration space 
of protein and precipitating agent, while the ratio of the two 
remains constant. It is thus only necessary to set-up differing 35 
ratios, whose concentration can be changed post-programming 
via evaporation or condensation. Finally, crystals formed in 
droplets and stored in glass capillaries can be placed directly 
into a beam line and subjected to x-ray diffraction, nicely 
integrating the process. 40 
 Droplet generation for high-throughput screening of 
crystallization conditions is a powerful approach that can be 
extended to the screening of other biochemical reactions. One 
limitation of the method is the fact that to-date only a limited 
number of fluid streams have been used for generating low-45 
dimensional mixtures of 3-4 substances. Higher dimensional 
mixtures of all commonly used crystallization reagents would 
be a major advance to the system, and likely achievable. A 
more fundamental limitation is the water / oil interface itself, 
which can potentially interfere with a large number of 50 
reactions, because of loss of hydrophic molecules to the oil 
phase or aggregation of labile molecules at the w/o interface. 
This may be solved to a certain extent with appropriate 
chemistries86. But, until a generic solution to this issue has 
been found, w/o emulsions and droplets are likely to be 55 
applicable only to a largely reduced number of reactions than 
would otherwise be possible.  
  
 
Fig. 5 Formulater Device (a) Optical micrograph of a formulator device. 60 
The central component is a mixing ring, which can be loaded with 
differing ratios of up to 32 solutions selected with the multiplexers seen 
on the left and bottom of the image. (b-d) Demonstration of how the 
mixing ring can be loaded with 3 different solutions (blue, yellow, and 
red), followed by rapid mixing (d). (reproduced with permission from 65 
reference 59) 
 Stephen Quake’s group at Stanford University has taken a 
different approach to protein crystallization by screening not 
directly for crystallization conditions, but rather for conditions 
that precipitate protein from solution (Fig. 5)59. Knowledge of 70 
the complete phase space of a protein should in principal aid 
crystallization efforts, as protein crystallization is likely to 
occur at the interface between the soluble and precipitating 
phases. 
 The microfluidic device designed by Hansen et al. is 75 
capable of rapidly combining and mixing arbitrary ratios of 32 
stock reagents. Each reagent can be selected on-chip via the 
use of a microfluidic multiplexer. Once selected, precise 
amounts of the reagent can be metered out by an integrated 
peristaltic pump and introduced into a ring-structure. Once all 80 
reagents including the protein are added, rapid mixing (<3 
seconds for aqueous and <6 seconds for viscous solutions) is 
achieved by pumping the solution around in a circle. Pumping 
causes the fluid lamina to fold over one another, effectively 
reducing the diffusion distance required for complete 85 
randomization of the molecules. Protein precipitation is 
detected by simple absorption measurements using a control 
solution as a baseline. A proof-of-principle experiment 
consisted of measuring the phase space of xylanase by 
screening ~4’000 precipitating reactions in quadruplicates, 90 
with each run requiring ~20h (giving rise to a throughput of 
roughly 3.3Hz) and consuming about 8uL of protein solution. 
Hansen et al. then went on to show that rationally chosen 
crystallization conditions from their phase-space diagrams 
resulted in an increased hit density as compared to standard 95 
sparse matrix screens. For screening protein crystallization 
conditions directly, the authors developed a systematic-
parallel screening platform capable of performing 144 
simultaneous crystallization screens by free interface 
diffusion58. 100 
 The formulator device is a good example of how complex 
fluidic manipulations can be achieved on a  
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Fig. 6 Matrix Device The device shown schematically in (a) is capable of running 400 individual PCR reactions, generated by combining 20 different 
primer pairs with 20 different templates. The primers, DNA templates and buffer solution are combined on chip via active mixing (b). (adapted with 
permission from reference 31) 
microfluidic platform. The fluidic complexity allowed the 5 
authors to combine roughly an order of magnitude more input 
streams than is possible to-date with droplet-based screening. 
On the other hand, the throughput of the formulator will most 
likely remain significantly below the conceptually achievable 
throughput of droplet-based devices. Furthermore, formulator 10 
throughput is strongly dependent on the length of time 
required for each reaction to take place. Slow reactions such 
as protein synthesis or crystallization can only be achieved if 
a storage loop87, 88 is added to the functionality of the 
formulator. A fusion device consisting of a formulator 15 
upstream of a droplet generator could be an optimal solution, 
eliminating the major drawbacks of both approaches. 
 Both the droplet based devices and the formulator could in 
principle be applied to a plethora of screening applications. 
These devices are particularly appropriate if exceedingly 20 
high-throughput, on the order of tens of thousands of 
reactions, is required. The main limitation of these approaches 
is the fact that diversity is achieved, in both cases, by mixing 
ratios of a rather small number of input solutions. Of course 
this is perfectly appropriate for experiments such as protein 25 
crystallization screens. When thousands of unique samples 
need to be interrogated the only choice probably lies with 
systematic-parallel devices described below. Yet, as alluded 
to above, the most powerful serial screening experiments will 
be of the random-serial type, which could be fused with these 30 
two methods to great effect. 
 
Parallel Devices 
Systematic-parallel screening devices generally consist of 
hundreds to thousands of unit cells. In each unit cell a unique 35 
reaction is taking place that can be either generated by pair 
wise combination of a small number of input reagents or 
programmed directly using a microarray-based method we 
recently developed55. 
 Liu et al. developed a device based on pair wise 40 
combinations of input solutions to generate 400 unique PCR 
reactions in parallel (Fig. 6)31. In a proof-of-principle 
experiment Liu generated a precise pattern of 100 positive and 
300 negative PCR reactions. The device allows for the 
separate introduction of 20 primer pairs, 20 templates, and 45 
one buffer solution. These three solutions can be mixed on-
chip followed by thermal cycling. Using this matrix approach 
requires only (N+M) + 1 pipetting steps to generate an entire  
NxM matrix of combinations. NxM arrays do indeed 
drastically reduce the number of necessary pipetting steps, but 50 
become cumbersome when N or M become large (>20), as 
each input has to be individually loaded and addressed. Better 
integration with multiwell plate formats for this step can 
potentially increase this number close to 100, giving rise to a 
feasible matrix size of 10’000. Finally, the matrix approach is 55 
only applicable to screens where complexity can be generated 
by combining multiple solutions (similar to the systematic-
serial screens), but it cannot be used when large libraries of 
unique components such as drug or other molecular libraries 
need to be tested directly. 60 
 Using a similar strategy, Lee et al. devised a microfluidic 
device capable of generating 64 parallel nanoliter sized 
chambers for culturing mammalian cells (Fig. 7)42. In this 
approach 8 columns could be individually loaded with cells 
followed by continuous perfusion of medium along the rows 65 
of the device. A concentration gradient89 could be generated 
across the rows to give rise to 64 distinct environments 
covering both genotypic and environmental diversity. The 
authors studied culturing conditions of HeLa cells covering 8 
different serum levels. Cell seeding density could be 70 
controlled to give rise to initial densities varying between 19 
to 42 cells per chamber and was independent of chamber 
index. Cells were grown on the device for a week without 
significant drops in cell viability making this approach 
applicable to experiments requiring long term cell culturing. 75 
Each chamber is optically accessible allowing for the 
determination of cellular phenotypes such as morphology and  
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Fig. 7 Microbioreactor Array (a) Image of the microbioreactor array device, filled with green dye for visualization of the flow channels. The device 
contains 64 individually addressable reactors (b). The device was used to screen cell growth at 8 different concentrations of serum (c).  (adapted with 
permission from reference 42) 
 5 
 
Fig. 8 Micrfluidic Cell Culture System A cell culturing system capable 
of generating 96 parallel, highly complex culturing conditions is depicted 
here. The device consists of 96 chambers, individually addressable by a 
multiplexer. Each chamber can be fed serially with a different medium 10 
recipe. Feeding recipes and schedules, as well as chip imaging are all 
completely automated. (Reproduced with permission from reference 44) 
fluorescent reporter gene expression. The approach suffers 
from the same limitations as the approach taken by Liu et al. 
in that only a limited number of unique solutions can be 15 
introduced. Additionally, the use of a gradient generator limits 
the second dimension to concentration gradients of a single 
substrate of interest, but this can be easily modified to include 
inputs for 8 unique solutions.  
 Gómez-Sjöberg et al. implemented a microfluidic platform 20 
capable of 96 independent culturing conditions in 60nL 
chambers (Fig. 8)44. Here the authors generate complexity by 
serially addressing each chamber. Cells could be loaded to 
precise densities by consecutive loading cycles. The precision 
of loading being only dependent on the initial cell density, 25 
with lower densities giving rise to more precise metering, 
while requiring more cycles to be performed for reaching 
higher densities. Once inoculated, each chamber could be fed 
with a complex mixture of up to 16 components mixed during 
the loading process. The entire device, including optical 30 
readout of each chamber, was highly automated, using 
software based control of the feeding schedule and device 
readout. The authors studied the differentiation of human 
primary mesenchymal stem cells (hMSCs) by varying both the 
initial seeding densities as well as the duration of stimulation. 35 
These complex culturing conditions are difficult to achieve 
using classical high-throughput culturing methods based on 
multiwell plates. Furthermore, for rare samples, microfluidic 
culturing entails huge benefits due to enormous reduction in 
material required.  40 
 Both cell-culturing devices discussed above achieve 
medium throughput on the order of a single 96-well plate. The 
advantage of the microfluidic approaches lie in the reduction 
of sample required and the increase in assay complexity. 
Being able to study multiple cell reaction chambers with both 45 
high temporal as well as spatial resolution is imperative in 
systems biology where network responses can occur both 
rapidly and on a scale only observable on the single cell 
level90-92. The ability to scale-up single cell measurements to 
include a large number of environmental conditions is 50 
paramount to understanding what the cellular responses are to 
these environments.  Even though these examples only 
achieved relatively low throughput on the order of 64 and 96 
parallel reactions, there is no doubt that future designs will 
achieve higher parallelization. 55 
 We have recently developed a high-throughput microfluidic 
platform for performing highly parallelized protein interaction 
measurements (Fig. 9) coupled to a novel detection 
mechanism based on the mechanically induced trapping of 
molecular interactions (MITOMI) capable of detecting 60 
transient interactions55. The devices consist of thousands of  
 8  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
 
Fig. 9 MITOMI Device (a) Schematic and (b) photo of the MITOMI device. The flow layer is shown in blue, the control layer is denoted in red. The 
device contains 2400 unit cells (d) and is controlled by 7233 valves. Each unit cell is programmed by aligning the device to a spotted microarray (c); DNA 
spots of varying sequence and concentration (green) are aligned to the microfluidic device, whose outlines are visible in red. (e) A novel detection 
mechanism based on the mechanically induced trapping of molecular interactions (MITOMI). MITOMI allows for thousands of parallel high-precision 5 
affinity measurements to be performed on a single device. ( (a,d,e) adapted with permission form reference 55)  
reaction chambers, which are individually programmed using 
a microarray. Microarrays are particularly well suited for 
integration with microfluidics since the process of 
microarraying consolidates existing libraries housed in 10 
multiwell plates on a small footprint that is compatible with 
microfluidic devices. Aligning of these printed microarrays to 
microfluidic devices programs each chamber with a single 
spot and compartmentalizes it, eliminating any potential for 
downstream cross-contamination. Finally, sample 15 
consumption is minimized as spotting consumes as little as 
250nL of sample, from which hundreds of sub-nanoliter spots 
can be generated. Other microfluidic methods generally suffer 
from large dead-volumes when coupling reagent reservoirs to 
the fluidic devices, leading to dead-volumes in the tens of 20 
microliters. Generating microarrays using standard spotting 
techniques is also extremely modular, allowing for the 
arraying of proteins, DNA, small molecules, and even 
colloidal suspensions. 
 Using this approach of programming microfluidic devices 25 
with microarrays we measured comprehensive binding energy 
landscapes for several transcription factors by experimentally 
determining the affinity of several transcription factors to 464 
different double-stranded DNA oligomers. Each oligomer was 
spotted in duplicate at 6 different concentrations. 2400 of such 30 
affinity measurements were taken in parallel on a single 
device, resulting in a total of over 41’000 unique affinity 
measurements determined on 17 devices. The transcription 
factor to be tested is synthesized on-chip from linear 
expression templates via in vitro transcription / translation. 35 
Fluorescent quantitation of the trapped material is done using 
a DNA microarray scanner, slightly modified to accept the 
microfluidic device. Such comprehensive measurements of the 
biophysical characteristics of a transcription factor allowed us 
to determine basic parameters governing transcription factor – 40 
DNA interactions, as well as reconstruct biological networks 
in silico using the binding energy landscapes determined in 
vitro. 
 Einav et al. applied this approach to characterizing the 
RNA binding of a hepatitis C membrane protein NS4B41. 45 
NS4B was found to specifically bind the 3’UTR of the 
negative strand of the viral RNA genome, implicating it in 
viral assembly. This in turn made it an interesting candidate 
for drug discovery. To this end Einav et al. spotted a 
commercially available small compound library encompassing 50 
1280 members and tested each of these compounds for 
interference between NS4B and RNA binding. The screen 
yielded 18 compounds that interfered with binding in vitro, of 
which one was shown to inhibit viral replication in vivo 
without negatively impacting cell viability.  55 
 Because the spotted arrays are compartmentalized it 
becomes feasible to spot multiple solutions onto a single spot 
on the array, which is consequently isolated on-chip. This 
allows users to generate multiplexed assays similar to those 
accomplished using the matrix device described by Liu et al. 60 
at the beginning of the section31. But, not only is it possible to 
test NxM combinations, one can also generate higher-
dimensional arrays consisting of NxMxK samples by spotting 
three or more unique substances on a single spot. 
 We took advantage of being able to generate arbitrary 65 
combinations of two samples by co-spotting a library of linear 
expression templates coding for 95 different transcription 
factor mutants with a library of 64 target DNA sequences 
(Maerkl and Quake, submitted). Each chamber, containing 
linear expression template for one mutant and one target DNA 70 
sequence, is flooded with in vitro transcription – translation 
reaction, which synthesizes the mutant protein. The 
transcription factor is consequently immobilized on the 
surface and binding to the target DNA sequence is measured. 
This approach allowed us to measure over 6’000 protein – 75 
DNA interactions using in situ synthesized transcription factor 
mutants. 
 In a second example of how co-spotting can be applied to 
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biological network characterization, Gerber et al. co-spotted 
all combinations of 43 linear expression templates, coding for 
43 different S.pneumoniae proteins (Gerber et al., submitted). 
The proteins were tested for direct protein-protein 
interactions, uncovering a rich protein interaction network. 5 
 The use of microarrays for programming microfluidic 
devices is a rapid approach with many advantages, including 
simple integration with existing libraries, extremely low 
sample consumption, high-throughput, and modularity. We 
have shown that a number of screening assays are possible 10 
with this approach and this number is likely to broaden 
considerably in the future. 
 Meyvantsson at al. recently developed a device to allow 
researcher to perform basic microfluidic experiments using 
standard laboratory liquid handling equipment such as pipettes 15 
and robotic platforms93. The device makes use of passive 
pumping to introduce liquids into the 96-192 channels located 
on each device. The channel interface follows the standard 
micro-titer plate standard to facilitate use with medium to 
high-throughput 8 channel pipettes and robotic liquid-20 
handling platforms, respectively. Simple fluidic manipulations 
such as pumping, routing, compartmentalization, and laminar 
flow could be achieved. Furthermore, the authors cultured 
mammalian cells for 5 days with media additions every 24 
hours. Meyvantsson et al. realized a low-tech microfluidic 25 
platform that can be used by researchers lacking specialized 
backgrounds in microfluidics and microfabrication, allowing 
these platforms to be more widely used than other more 
complex system (the issue of increasing accessibility to 
microfluidic platforms is also discussed in the conclusions). 30 
 Finally, centrifuge-based microfluidic platforms have also 
been broadly applied to standard methods in biology, such as 
ELISA assays94, cell viability assays, PCR, and mass 
spectrometry, which have all been comprehensively reviewed 
by Madou95. CD based systems generally consist of several 35 
dozens of parallel reaction chambers arranged radially on a 
CD type substrate. Assays are capable of mixing several input 
streams, serial addition of samples, hydrophobic and capillary 
based valving, and precise metering95.  
Systematic Devices Summary 40 
Systematic screens are useful for many applications since the 
exact identity of each reaction is known a priori. It is thus 
possible to screen a large number of reactions, which as a 
whole provide an answer to complex problems and systems. 
Systematic screens often lag behind random screens in 45 
throughput. This is acceptable though, as many libraries that 
exist today comprise on the order of thousands to tens of 
thousands of members. Systematic screens have been 
developed for both chemical41, biochemical55, and cell based 
assays42, 44, indicating their versatility. And with fields such as 50 
systems biology putting ever more emphasis on global screens 
of cellular function and biochemistry, microfluidic based 
systematic screens are likely to become more broadly used in 
the near future. 
Hybrid Devices 55 
Microfluidic screens of course do not have to be exclusively 
serial or parallel. Hybrid devices can easily be generated by 
either parallelizing multiple serial screening experiments on a 
single platform or by running a parallel device multiple times 
in series. Droplet devices such as those applied to systematic 60 
crystallization screens could for example be parallelized, 
allowing multiple precipitating agents and combinations 
thereof to be screened simultaneously. Parallel devices on the 
other hand can often be serialized, giving rise to large gains in 
throughput. The cell screening devices described by Lee42 and 65 
Gómez-Sjöberg44 are already capable of such serialization 
through performing a number of varying perfusion/feeding 
experiments. 
 Random and systematic screens can also be combined. One 
example would be an initial round of screening and selection 70 
on a heterogeneous population of cells, followed by 
systematic screens on the selected sub-population. Rohde et 
al. propose such an approach by combining a number of 
devices they designed for screening and handling C. elegans, 
including a high-throughput sorter, a parallel screening 75 
device, and a multiwell plate interface48. 
Conclusions 
The field of microfluidics has made significant progress over 
the last decade, leading to the development of highly-
integrated screening platforms. A number of proof-of-80 
principle experiments have shown that this technology can be 
applied to systems biology55, 92, 96, 97, promising to widen 
many bottlenecks that constrict advances in biology today. 
 Research labs will continue to develop novel and more 
highly-integrated devices in the future albeit dissemination of 85 
this technology has progressed at a much slower pace. It is 
absolutely necessary to port developments made in the 
research lab to commercially available platforms. Developing 
advanced world-to-chip interfaces, and simplifying chip usage 
will be paramount in achieving broad acceptance of this 90 
technology by the intended users. Arguably, these kinds of 
improvements are most appropriately solved by companies 
interested in commercializing microfluidics, while the 
research community continues to explore the frontiers of the 
field of microfluidics. Most universities have the required 95 
infrastructure for fabricating many, if not all, of the devices 
described herein. For those universities that lack the 
infrastructure or expertise, microfluidic foundries are 
available at Caltech (http://kni.caltech.edu/foundry/) and 
Stanford University (http://thebigone.stanford.edu/foundry/). 100 
These foundries will fabricate custom designed molds and 
PDMS based microfluidic devices at minimal cost to the user. 
 Another critical component in the development of fluidic 
technology will be the integration with detection mechanisms. 
Many promising detectors have recently been demonstrated, 105 
either based on solid state optics1, MEMS/NEMS devices11, or 
CMOS based chemical sensors98. Successful integration of 
other novel technologies with microfluidics will generate 
more compact and portable devices, as well as potentially 
entail much higher detection sensitivities as those currently 110 
achievable. 
 The potential of microfluidics for impacting the biological 
sciences is apparent. A number of microfluidic based assays 
 10  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
have already provided novel insights into the structure and 
function of biological systems, and the field of microfluidics 
will continue to impact biology, because biology has long 
outgrown its 8-strip PCR tubes and 96 well plates. 
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